Stillfront Group announced that Marcus Jacobs will become the new President and Group CEO starting November 1, succeeding Alexis Bonte who led the company through strategic changes. Jacobs brings extensive industry experience, including executive roles at King and Candy Crush, and has been on Stillfront's Board for nearly four years. The leadership change aims to continue executing Stillfront's strategy and strengthen its key franchises. The outgoing CEO, Alexis Bonte, will assist with the transition after November 1.
Stillfront Group AB's leadership change is the subject here, provided with Technology sector market context from Pluang. For readers following Technology stocks, 81 of 150 priced US stocks rose and 68 fell today. Notable movers include CRWD at USD 252.00 with a 1-day change of +5.91% and a Pluang order activity split of 47% Sell / 53% Buy, INFY at USD 12.47 down -5.67% with 100% Sell orders, and ZS at USD 250.32 up +5.28% with 34% Sell / 66% Buy. This data is as of Oct 24, 2026 00:11 WIB.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
